Socio-demographic and economic inequalities in modern contraception in 11 low- and middle-income countries: an analysis of the PMA2020 surveys.


Journal

Reproductive health
ISSN: 1742-4755
Titre abrégé: Reprod Health
Pays: England
ID NLM: 101224380

Informations de publication

Date de publication:
01 Jun 2020
Historique:
received: 29 11 2019
accepted: 22 05 2020
entrez: 4 6 2020
pubmed: 4 6 2020
medline: 16 3 2021
Statut: epublish

Résumé

Contraception is a key component of sustainable development, empowering women, reducing the risk of maternal and child mortality and promoting economic growth. It is part of the Sustainable Development Goals agenda, where the aim is to achieve universal access to sexual and reproductive health. Our objective was to evaluate trends and inequalities in modern contraceptive prevalence, and according to the type of modern contraceptive, in 11 low- and middle-income countries that are partners of the Family Planning 2020 initiative. Analyses were performed using 62 Performance Monitoring and Accountability 2020 (PMA2020) surveys from 11 countries. Forty surveys were nationally representative, while 22 had regional coverage. Regional surveys were analyzed separately, totalizing 15 geographies from 11 countries. We described trends on modern contraceptive prevalence, and its subtypes (short- and long-acting reversible contraceptives, and permanent methods), by calculating absolute average annual changes. Absolute inequalities on the prevalence of modern contraceptives were assessed for the most recent survey of each geography using the slope index of inequality, and according to wealth, education and age. The overall prevalence of modern contraception increased in most geographies analyzed, reaching a 7.2 percentage points increase per year in Lagos, Nigeria. This increase was mostly influenced by the long-acting reversible contraceptives, which increased in 73% of the geographies. Although the largest share of modern contraception is represented by short-acting reversible contraceptives, these are reducing and giving space for the long-acting methods. The exception was Rajasthan, India, where the permanent methods accounted for 70% of the modern contraception share, and their prevalence was almost 40%. Inequalities were identified in favor of richer, older and better educated women. Out of the 15 geographies analyzed, 11 demonstrated an increase in overall modern contraceptive use - mainly driven by the uptake of long-acting reversible contraception. However, even in the groups with the highest prevalence, modern contraceptive use was at most 60% in most geographies. So, we are far from reaching the desired universal coverage proposed by the Sustainable Development Goals.

Sections du résumé

BACKGROUND BACKGROUND
Contraception is a key component of sustainable development, empowering women, reducing the risk of maternal and child mortality and promoting economic growth. It is part of the Sustainable Development Goals agenda, where the aim is to achieve universal access to sexual and reproductive health. Our objective was to evaluate trends and inequalities in modern contraceptive prevalence, and according to the type of modern contraceptive, in 11 low- and middle-income countries that are partners of the Family Planning 2020 initiative.
METHODS METHODS
Analyses were performed using 62 Performance Monitoring and Accountability 2020 (PMA2020) surveys from 11 countries. Forty surveys were nationally representative, while 22 had regional coverage. Regional surveys were analyzed separately, totalizing 15 geographies from 11 countries. We described trends on modern contraceptive prevalence, and its subtypes (short- and long-acting reversible contraceptives, and permanent methods), by calculating absolute average annual changes. Absolute inequalities on the prevalence of modern contraceptives were assessed for the most recent survey of each geography using the slope index of inequality, and according to wealth, education and age.
RESULTS RESULTS
The overall prevalence of modern contraception increased in most geographies analyzed, reaching a 7.2 percentage points increase per year in Lagos, Nigeria. This increase was mostly influenced by the long-acting reversible contraceptives, which increased in 73% of the geographies. Although the largest share of modern contraception is represented by short-acting reversible contraceptives, these are reducing and giving space for the long-acting methods. The exception was Rajasthan, India, where the permanent methods accounted for 70% of the modern contraception share, and their prevalence was almost 40%. Inequalities were identified in favor of richer, older and better educated women.
CONCLUSIONS CONCLUSIONS
Out of the 15 geographies analyzed, 11 demonstrated an increase in overall modern contraceptive use - mainly driven by the uptake of long-acting reversible contraception. However, even in the groups with the highest prevalence, modern contraceptive use was at most 60% in most geographies. So, we are far from reaching the desired universal coverage proposed by the Sustainable Development Goals.

Identifiants

pubmed: 32487182
doi: 10.1186/s12978-020-00931-w
pii: 10.1186/s12978-020-00931-w
pmc: PMC7268403
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

82

Subventions

Organisme : Bill & Melinda Gates Foundation
ID : OPP1199234
Pays : United States
Organisme : Wellcome Trust
ID : 101815/Z/13/Z
Pays : United Kingdom

Références

Int Q Community Health Educ. 2012-2013;33(4):403-13
pubmed: 24044930
Lancet Glob Health. 2017 Mar;5(3):e242-e243
pubmed: 28193384
Contraception. 2015 Nov;92(5):420-1
pubmed: 26276245
Lancet Glob Health. 2019 Jul;7(7):e904-e911
pubmed: 31109881
PLoS One. 2019 Jul 16;14(7):e0219617
pubmed: 31310641
Lancet. 2012 Jul 14;380(9837):165-71
pubmed: 22784535
Reprod Health. 2019 Feb 21;16(1):21
pubmed: 30791914
J Obstet Gynaecol. 2002 Sep;22(5):540-3
pubmed: 12521426
PLoS Med. 2013;10(5):e1001390
pubmed: 23667332
J Family Med Prim Care. 2019 Oct 31;8(10):3297-3302
pubmed: 31742159
BMJ. 2019 Apr 1;365:l1228
pubmed: 30936210
Reprod Health. 2019 Oct 11;16(1):148
pubmed: 31601246
Lancet Glob Health. 2019 Feb;7(2):e227-e235
pubmed: 30683240
Contracept Reprod Med. 2017 Feb 2;2:10
pubmed: 29201415
Glob Health Action. 2015 Nov 09;8:29737
pubmed: 26562143
BMC Public Health. 2010 Sep 03;10:530
pubmed: 20813069
Lancet Glob Health. 2017 Jan;5(1):e104-e114
pubmed: 27955769
Reprod Health. 2018 Mar 6;15(1):42
pubmed: 29510682
Health Policy Plan. 2008 Nov;23(6):465-75
pubmed: 18796500
J Biosoc Sci. 2015 May;47(3):345-62
pubmed: 24911333
Lancet. 2013 May 11;381(9878):1642-52
pubmed: 23489750
Lancet. 2006 Nov 18;368(9549):1810-27
pubmed: 17113431
Bull World Health Organ. 2014 Aug 1;92(8):548-548A
pubmed: 25177066
Glob Health Action. 2015 Nov 09;8:29735
pubmed: 26562141
Lancet. 2018 Nov 10;392(10159):1995-2051
pubmed: 30496106
Lancet. 1990 Jan 27;335(8683):224-5
pubmed: 1967685

Auteurs

Cauane Blumenberg (C)

International Center for Equity in Health (ICEH), Federal University of Pelotas, Rua Marechal Deodoro 1160, 3o piso, Pelotas, RS, 96020-220, Brazil. cblumenberg@equidade.org.

Franciele Hellwig (F)

International Center for Equity in Health (ICEH), Federal University of Pelotas, Rua Marechal Deodoro 1160, 3o piso, Pelotas, RS, 96020-220, Brazil.
Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas, RS, Brazil.

Fernanda Ewerling (F)

International Center for Equity in Health (ICEH), Federal University of Pelotas, Rua Marechal Deodoro 1160, 3o piso, Pelotas, RS, 96020-220, Brazil.

Aluísio J D Barros (AJD)

International Center for Equity in Health (ICEH), Federal University of Pelotas, Rua Marechal Deodoro 1160, 3o piso, Pelotas, RS, 96020-220, Brazil.
Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas, RS, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH